135 related articles for article (PubMed ID: 24843579)
1. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.
Kozawa J; Inoue K; Iwamoto R; Kurashiki Y; Okauchi Y; Kashine S; Kitamura T; Maeda N; Okita K; Iwahashi H; Funahashi T; Imagawa A; Shimomura I
J Diabetes Investig; 2012 Jun; 3(3):294-7. PubMed ID: 24843579
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.
Kozawa J; Kitamura T; Nishizawa H; Yasuda T; Maeda N; Otsuki M; Okita K; Iwahashi H; Kaneto H; Funahashi T; Imagawa A; Shimomura I
J Diabetes Investig; 2013 Mar; 4(2):190-4. PubMed ID: 24843651
[TBL] [Abstract][Full Text] [Related]
3. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.
Kondo Y; Satoh S; Nagakura J; Kimura M; Nezu U; Terauchi Y
J Diabetes Investig; 2013 Nov; 4(6):571-5. PubMed ID: 24843711
[TBL] [Abstract][Full Text] [Related]
4. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.
Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Takahara S; Nagashima K; Hosokawa M; Seino Y; Inagaki N
J Diabetes Investig; 2011 Aug; 2(4):297-303. PubMed ID: 24843502
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin.
Nambu T; Matsuda Y; Matsuo K; Kanai Y; Yonemitsu S; Muro S; Oki S
J Diabetes Investig; 2013 Jan; 4(1):69-77. PubMed ID: 24843633
[TBL] [Abstract][Full Text] [Related]
6. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
7. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
8. C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.
Ohbatake A; Yagi K; Karashima S; Shima Y; Miyamoto Y; Asaka H; Okazaki S; Kometani M; Kawashiri MA; Takeda Y; Yoneda T; Chujo D
Diabetes Ther; 2019 Apr; 10(2):673-681. PubMed ID: 30788807
[TBL] [Abstract][Full Text] [Related]
9. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
10. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.
Fujiwara D; Takahashi K; Suzuki T; Shii M; Nakashima Y; Takekawa S; Yoshida A; Matsuoka T
J Diabetes Investig; 2013 Nov; 4(6):618-25. PubMed ID: 24843717
[TBL] [Abstract][Full Text] [Related]
11. Short-term recovery of insulin secretion in response to a meal is associated with future glycemic control in type 2 diabetes patients.
Enkaku A; Chujo D; Kamigishi M; Inagawa S; Matsukoshi S; Sakai W; Takikawa A; Fujisaka S; Tobe K
J Diabetes Investig; 2024 Apr; 15(4):437-448. PubMed ID: 38151917
[TBL] [Abstract][Full Text] [Related]
12. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes.
Okuno Y; Sakaguchi K; Komada H; Hashimoto N; Hirota Y; Nakamura T; Ogawa W; Seino S
Kobe J Med Sci; 2013 Apr; 59(2):E44-53. PubMed ID: 23756662
[TBL] [Abstract][Full Text] [Related]
13. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
Kaneko S; Ueda Y; Tahara Y
Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
Kielgast U; Holst JJ; Madsbad S
Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
[TBL] [Abstract][Full Text] [Related]
15. Preoperative insulin secretion ability and pancreatic parenchymal thickness as useful parameters for predicting postoperative insulin secretion in patients undergoing pancreaticoduodenectomy.
Yoshikawa A; Kozawa J; Okita K; Yoneda S; Okauchi Y; Uno S; Iwahashi H; Ohira T; Takiuchi D; Eguchi H; Takeda Y; Imagawa A; Shimomura I
Endocr J; 2012; 59(5):383-92. PubMed ID: 22374239
[TBL] [Abstract][Full Text] [Related]
16. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.
Usui R; Yabe D; Kuwata H; Fujiwara S; Watanabe K; Hyo T; Yasuhara A; Iwasaki M; Kitatani N; Kuwabara K; Yokota K; Kurose T; Seino Y
J Diabetes Investig; 2013 Nov; 4(6):585-94. PubMed ID: 24843713
[TBL] [Abstract][Full Text] [Related]
18. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.
Kaku K; Rasmussen MF; Nishida T; Seino Y
J Diabetes Investig; 2011 Nov; 2(6):441-7. PubMed ID: 24843528
[TBL] [Abstract][Full Text] [Related]
19. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
Ellenbroek JH; Töns HA; Westerouen van Meeteren MJ; de Graaf N; Hanegraaf MA; Rabelink TJ; Carlotti F; de Koning EJ
Diabetologia; 2013 Sep; 56(9):1980-6. PubMed ID: 23771206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
